Camurus Future Growth

Future criteria checks 6/6

Camurus is forecast to grow earnings and revenue by 75% and 41.3% per annum respectively. EPS is expected to grow by 74.9% per annum. Return on equity is forecast to be 40.3% in 3 years.

Key information

75.0%

Earnings growth rate

74.9%

EPS growth rate

Pharmaceuticals earnings growth	66.8%
Revenue growth rate	41.3%
Future return on equity	40.3%
Analyst coverage	Good
Last updated	19 Jul 2024

Recent future growth updates

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Jul 19

Recent updates

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Jul 19

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Jul 12

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Nov 11

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Feb 22

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Apr 30

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Dec 09

Earnings and Revenue Growth Forecasts

OM:CAMX - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	4,428	1,865	1,652	1,667	4
12/31/2025	3,210	1,155	941	957	6
12/31/2024	1,949	377	229	241	6
6/30/2024	1,593	223	643	651	N/A
3/31/2024	1,823	450	609	619	N/A
12/31/2023	1,717	431	597	607	N/A
9/30/2023	1,610	460	614	622	N/A
6/30/2023	1,468	408	191	190	N/A
3/31/2023	1,020	115	138	133	N/A
12/31/2022	956	56	107	101	N/A
9/30/2022	871	28	21	18	N/A
6/30/2022	784	-13	-44	-39	N/A
3/31/2022	695	-69	-96	-90	N/A
12/31/2021	601	-90	-148	-143	N/A
9/30/2021	523	-142	-182	-179	N/A
6/30/2021	470	-156	-212	-209	N/A
3/31/2021	413	-128	-237	-234	N/A
12/31/2020	336	-167	-242	-239	N/A
9/30/2020	265	-174	-283	-270	N/A
6/30/2020	205	-216	-339	-324	N/A
3/31/2020	136	-284	-401	-380	N/A
12/31/2019	106	-290	-430	-404	N/A
9/30/2019	78	-305	-397	-381	N/A
6/30/2019	58	-286	-382	-367	N/A
3/31/2019	53	-266	-326	-317	N/A
12/31/2018	49	-235	-279	-274	N/A
9/30/2018	47	-200	-252	-249	N/A
6/30/2018	40	-208	-221	-218	N/A
3/31/2018	52	-187	N/A	-207	N/A
12/31/2017	54	-191	N/A	-203	N/A
9/30/2017	86	-166	N/A	-156	N/A
6/30/2017	104	-127	N/A	-142	N/A
3/31/2017	111	-102	N/A	-107	N/A
12/31/2016	114	-81	N/A	-208	N/A
9/30/2016	113	-85	N/A	-161	N/A
6/30/2016	120	-95	N/A	-155	N/A
3/31/2016	116	-189	N/A	-109	N/A
12/31/2015	155	-160	N/A	-6	N/A
9/30/2015	263	-53	N/A	101	N/A
12/31/2014	208	48	N/A	69	N/A
12/31/2013	198	99	N/A	163	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CAMX's forecast earnings growth (75% per year) is above the savings rate (1.1%).

Earnings vs Market: CAMX's earnings (75% per year) are forecast to grow faster than the Swedish market (15.8% per year).

High Growth Earnings: CAMX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CAMX's revenue (41.3% per year) is forecast to grow faster than the Swedish market (1.1% per year).

High Growth Revenue: CAMX's revenue (41.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CAMX's Return on Equity is forecast to be very high in 3 years time (40.3%).

Camurus Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Consensus EPS estimates increase by 18%

Consensus EPS estimates fall by 39%

Camurus AB Provides Earnings Guidance for the Full Year 2024

Price target increased by 8.2% to kr550

Price target increased by 16% to kr471

Recent updates

New minor risk - Insider selling

Chief Technology Officer recently sold kr6.8m worth of stock

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Second quarter 2024 earnings: EPS misses analyst expectations

Camurus Announces Positive Phase 3 Results from the Acroinnova 2 Study of Octreotide Sc Depot (Cam2029) in Acromegaly Patients

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study

Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot (Cam2029) for the Treatment of Acromegaly

Chief Technology Officer recently sold kr845k worth of stock

Consensus EPS estimates increase by 18%

First quarter 2024 earnings released: EPS: kr1.36 (vs kr1.06 in 1Q 2023)

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Camurus AB (Publ) Announces Board Resignations

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Consensus EPS estimates fall by 39%

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.2% to kr550

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

President exercised options to buy kr86m worth of stock.

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Price target increased by 16% to kr471

Investor sentiment improves as stock rises 20%

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to kr351

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Insider recently sold kr295k worth of stock

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

New major risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

President recently sold kr23m worth of stock

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

Consensus EPS estimates increase by 21%

Consensus EPS estimates increase by 25%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Price target decreased by 7.3% to kr287

Third quarter 2022 earnings released: EPS: kr0.63 (vs kr0.11 loss in 3Q 2021)

Consensus EPS estimates increase by 17%

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023

Consensus forecasts updated

Camurus Announces PDUFA Date for Brixadi NDA for the Treatment of Opioid Use Disorder in the US

Forecast to breakeven in 2022

Price target increased to kr305

Camurus AB (Publ) Provides Earnings Guidance for the Year 2022

Price target increased to kr283

Camurus AB (publ), Annual General Meeting, May 10, 2023

Camurus AB (publ) to Report Fiscal Year 2022 Final Results on Mar 30, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Camurus AB (Publ) Raises Operating Result Guidance for the Full Year 2022

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

Vice President exercised options and sold kr178k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations